Table 3.
Clinical significance of overall somatic mutational status and selectively of somatic mutations in the CDH1 and TP53 genes in patients with gastric cancer.
| Number of cases | mut+ | Р value | mut− | CDH1 mut+ | Р value | TP53 mut+ | Р value | |
|---|---|---|---|---|---|---|---|---|
| Total number of patients | 77 | 32 | 45 | 11 | 13 | |||
|
Men Women |
47 30 |
17 15 |
0.24 |
30 15 |
5 6 |
0.32 |
7 6 |
0.55 |
|
Age 27–49 50–79 27–45 |
35 42 21 |
13 19 8 |
0.49 |
22 23 13 |
7 4 4 |
0.21 |
5 8 3 |
0.76 |
|
T1-2 T3-4 cis |
21 54 2 |
6 25 1 |
0.36 |
15 29 1 |
3 7 1 |
0.33 |
2 11 0 |
0.43 |
|
Lymph node metastases N0 N1-3 |
28 49 |
11 21 |
0.81 |
17 28 |
2 9 |
0.31 |
5 8 |
1.0 |
|
Metastasis No Yes |
41 36 |
14 18 |
0.17 |
27 18 |
2 9 |
0.019 |
5 8 |
0.36 |
|
Stage I-II III-IV |
29 48 |
8 24 |
0.06 |
21 24 |
2 9 |
0.19 |
3 10 |
0.34 |
|
5-year survival status Dead Alive N/A (onset less than 5 years ago) |
41 28 7 |
21 9 2 |
0.17 |
20 19 6 |
6 4 1 |
0.99 |
9 3 1 |
0.44 |
|
Loren classification Diffuse Intestinal Not classified |
38 29 10 |
13 15 4 |
0.35 |
25 14 6 |
5 3 3 |
0.29 |
5 7 1 |
0.4 |
|
Signet ring cells Yes No |
27 50 |
10 22 |
0.63 |
17 28 |
7 4 |
0.043 |
3 10 |
0.52 |